| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.0032 | 0.9 |